|
CN105121467B
(zh)
|
2012-12-03 |
2019-07-05 |
诺夫免疫股份有限公司 |
抗cd47抗体及其使用方法
|
|
JP2017515464A
(ja)
|
2014-04-10 |
2017-06-15 |
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
細胞免疫療法のための方法および組成物
|
|
EP4219687B1
(en)
|
2014-04-23 |
2024-08-14 |
Juno Therapeutics, Inc. |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
EP3209690B1
(en)
|
2014-10-20 |
2021-05-05 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
|
WO2018126369A1
(en)
|
2017-01-05 |
2018-07-12 |
Shanghai Sidansai Biotechnology Co., Ltd |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
AU2016306209B2
(en)
|
2015-08-07 |
2023-07-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific CAR T-cells for solid tumor targeting
|
|
EP3380126A4
(en)
|
2015-11-25 |
2019-07-24 |
LegoChem Biosciences, Inc. |
ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS
|
|
US11413353B2
(en)
|
2015-11-25 |
2022-08-16 |
Legochem Biosciences, Inc. |
Conjugates comprising self-immolative groups and methods related thereto
|
|
CN108136038A
(zh)
|
2015-11-25 |
2018-06-08 |
乐高化学生物科学股份有限公司 |
包含肽基团的缀合物及其相关方法
|
|
AU2017276706B2
(en)
*
|
2016-06-07 |
2024-08-15 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and CAR-T cells that bind BCMA
|
|
CN107793479B
(zh)
*
|
2016-09-06 |
2024-02-06 |
上海吉倍生物技术有限公司 |
一种抗cd19抗体及其制备方法和用途
|
|
CA3040812A1
(en)
*
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
|
EP3556772A4
(en)
*
|
2016-12-13 |
2020-09-09 |
Carsgen Therapeutics Ltd |
HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
|
|
WO2018132494A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
CA3053305A1
(en)
|
2017-02-17 |
2018-08-23 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies and cocktails for treatment of ebola infections
|
|
WO2018157171A2
(en)
|
2017-02-27 |
2018-08-30 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
WO2018170188A2
(en)
|
2017-03-14 |
2018-09-20 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
JP7664680B2
(ja)
|
2017-03-29 |
2025-04-18 |
リガケム バイオサイエンシズ， インク． |
ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
CA3065120A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
AU2018281316B2
(en)
|
2017-06-07 |
2024-05-30 |
Precigen, Inc. |
Expression of novel cell tags
|
|
EP3441471A1
(en)
*
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
MX2020001490A
(es)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
|
|
MX2020001491A
(es)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos y composiciones para preparar celulas geneticamente modificadas.
|
|
MA50057A
(fr)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
US20200207844A1
(en)
*
|
2017-09-12 |
2020-07-02 |
Igc Bio, Inc. |
Anti-vegf antibody
|
|
ES2960419T3
(es)
*
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
KR20230007557A
(ko)
*
|
2017-09-22 |
2023-01-12 |
카이트 파마 인코포레이티드 |
키메라 폴리펩티드 및 그의 용도
|
|
IL273424B2
(en)
|
2017-09-22 |
2024-09-01 |
Wuxi Biologics Ireland Ltd |
Novel bispecific cd3/cd19 polypeptide complexes
|
|
IL273217B2
(en)
|
2017-09-22 |
2025-04-01 |
Wuxi Biologics Ireland Ltd |
Novel bispecific polypeptide complexes
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
US20210254000A1
(en)
|
2017-11-01 |
2021-08-19 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
|
AU2018362014A1
(en)
|
2017-11-03 |
2020-05-28 |
Sorrento Therapeutics, Inc. |
CD38-directed chimeric antigen receptor constructs
|
|
KR102802061B1
(ko)
*
|
2017-11-10 |
2025-05-02 |
주라 바이오, 인크. |
주 조직적합성 복합체-기반 키메라 수용체 및 자가면역 질병을 치료하기 위한 이의 용도
|
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
EP3722313A4
(en)
|
2017-12-06 |
2021-02-24 |
AbClon Inc. |
ANTIBODY OR ITS BINDING FRAGMENT TO THE ANTIGEN TO SPECIFICALLY RECOGNIZE A B-CELL MALIGNITY, CHEMERIC ANTIGEN RECEPTOR INCLUDING IT, AND ITS USE
|
|
KR102862251B1
(ko)
|
2017-12-08 |
2025-09-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법을 위한 표현형 마커 및 관련 방법
|
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたｔ細胞の組成物を製造するための方法
|
|
CA3084569A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
KR102492115B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
|
|
JP7080514B2
(ja)
|
2017-12-22 |
2022-06-06 |
アブクロン・インコーポレイテッド |
悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
|
|
CN107903326B
(zh)
*
|
2018-01-02 |
2020-06-30 |
广东省人民医院(广东省医学科学院) |
包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
EP4227302A1
(en)
|
2018-02-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2019178356A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, t cell immune modulating antibodies and methods for using the same
|
|
CA3093810A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
WO2019200056A2
(en)
|
2018-04-12 |
2019-10-17 |
Vivo-Til Therapeutics Inc. |
Viral vectors and packaging cell lines
|
|
AR114789A1
(es)
*
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
SG11202010642TA
(en)
|
2018-05-03 |
2020-11-27 |
Juno Therapeutics Inc |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
KR20210023839A
(ko)
*
|
2018-05-09 |
2021-03-04 |
주식회사 레고켐 바이오사이언스 |
항-cd19 항체 약물 접합체 관련 조성물 및 방법
|
|
DK3793565T3
(en)
|
2018-05-14 |
2022-03-07 |
Gilead Sciences Inc |
Mcl-1-inhibitorer
|
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
|
US12486514B2
(en)
|
2018-08-29 |
2025-12-02 |
National University Of Singapore |
Method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
HRP20240541T1
(hr)
|
2018-10-31 |
2024-07-05 |
Gilead Sciences, Inc. |
Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1
|
|
BR112021008133A2
(pt)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
Métodos para seleção e estimulação de células e aparelhos para os mesmos
|
|
AU2019374790A1
(en)
|
2018-11-06 |
2021-05-27 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered T cells
|
|
CA3118830A1
(en)
*
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
|
CA3120118A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
CA3120363A1
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
|
DK3886875T3
(da)
|
2018-11-30 |
2024-07-29 |
Juno Therapeutics Inc |
Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi
|
|
CN111253487B
(zh)
*
|
2018-12-03 |
2024-02-02 |
广东东阳光药业股份有限公司 |
Cd19抗体及其应用
|
|
CA3122762A1
(en)
|
2018-12-12 |
2020-06-18 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
|
CN109734813B
(zh)
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
US12241061B2
(en)
|
2019-02-04 |
2025-03-04 |
National University Corporation Ehime University |
CAR library and scFv manufacturing method
|
|
CN113874391B
(zh)
|
2019-02-20 |
2025-10-28 |
希望之城公司 |
靶向baff-r/cd19的嵌合抗原受体修饰的t细胞及其用途
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US12318403B2
(en)
|
2019-03-07 |
2025-06-03 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
US20230065784A1
(en)
|
2019-03-21 |
2023-03-02 |
City Of Hope |
Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
SG11202113356XA
(en)
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
WO2020253879A1
(zh)
*
|
2019-06-21 |
2020-12-24 |
甘李药业股份有限公司 |
一种双特异性嵌合抗原受体
|
|
BR112021026376A2
(pt)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
Proteínas de fusão flt3l-fc e métodos de uso
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN112210007B
(zh)
*
|
2019-07-11 |
2022-07-12 |
华夏英泰（北京）生物技术有限公司 |
一种cd19抗原高亲和力的抗体以及包含其cd19单链抗体区的嵌合抗原受体
|
|
CN120484131A
(zh)
*
|
2019-07-19 |
2025-08-15 |
费城儿童医院 |
包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
CN114555112A
(zh)
|
2019-08-22 |
2022-05-27 |
朱诺治疗学股份有限公司 |
T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
PL4045083T3
(pl)
|
2019-10-18 |
2024-05-13 |
Forty Seven, Inc. |
Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
|
|
EP4051402A1
(en)
|
2019-10-30 |
2022-09-07 |
Juno Therapeutics GmbH |
Cell selection and/or stimulation devices and methods of use
|
|
JP7704748B2
(ja)
*
|
2019-10-31 |
2025-07-08 |
インサイト・コーポレイション |
逐次抗ｃｄ１９治療
|
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
|
BR112022007548A2
(pt)
|
2019-11-07 |
2022-07-12 |
Juno Therapeutics Inc |
Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
BR112022010310A2
(pt)
|
2019-12-06 |
2022-08-16 |
Juno Therapeutics Inc |
Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b
|
|
US11845723B2
(en)
|
2019-12-24 |
2023-12-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
US20230073449A1
(en)
|
2020-01-23 |
2023-03-09 |
The Children's Medical Center Corporation |
Stroma-free t cell differentiation from human pluripotent stem cells
|
|
JP2023513434A
(ja)
|
2020-01-24 |
2023-03-31 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法
|
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 형질도입 방법
|
|
CA3169672A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
CR20220396A
(es)
|
2020-02-14 |
2022-11-14 |
Jounce Therapeutics Inc |
Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
EP4143194A1
(en)
|
2020-05-01 |
2023-03-08 |
Gilead Sciences, Inc. |
Cd73 inhibiting 2,4-dioxopyrimidine compounds
|
|
CN115803824A
(zh)
|
2020-05-13 |
2023-03-14 |
朱诺治疗学股份有限公司 |
鉴定与临床反应相关的特征的方法及其用途
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
|
KR20230152783A
(ko)
|
2020-07-07 |
2023-11-03 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
US20230406922A1
(en)
|
2020-11-20 |
2023-12-21 |
Simcere Zaiming Pharmaceutical Co., Ltd. |
Humanized cd19 antibody and use thereof
|
|
MX2023005491A
(es)
|
2020-11-24 |
2023-08-09 |
Lyell Immunopharma Inc |
Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
JP2024502094A
(ja)
|
2020-12-30 |
2024-01-17 |
アラウノス セラピューティクス インコーポレイテッド |
多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
|
|
MX2023008081A
(es)
|
2021-01-11 |
2023-09-12 |
Sana Biotechnology Inc |
Uso de vectores virales dirigidos a cd8.
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
CN117321200A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
评估病毒载体颗粒效力的方法
|
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
EP4313126A1
(en)
|
2021-03-29 |
2024-02-07 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
AU2022297367B2
(en)
|
2021-06-23 |
2025-04-10 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117377671A
(zh)
|
2021-06-23 |
2024-01-09 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
Diacylglyercol kinase modulating compounds
|
|
EP4368640A4
(en)
*
|
2021-07-09 |
2025-01-22 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
Cd19 antibody and application thereof
|
|
CN117980326A
(zh)
|
2021-07-14 |
2024-05-03 |
2赛文缇生物公司 |
与来自抗体的结合结构域融合的经工程化的t细胞受体
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
US20240368626A1
(en)
*
|
2021-08-06 |
2024-11-07 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
T-cell manufacturing methods
|
|
CN118103403A
(zh)
*
|
2021-10-18 |
2024-05-28 |
凯德药业股份有限公司 |
嵌合抗原受体的信号传导结构域
|
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024545193A
(ja)
|
2021-12-22 |
2024-12-05 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4499146A1
(en)
|
2022-03-24 |
2025-02-05 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
CA3246975A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Vygen-Bio, Inc. |
Genetically modified antibody-resistant cells for adoptive cell therapy
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
JP2025513801A
(ja)
|
2022-04-08 |
2025-04-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多部位受容体及びシグナル伝達複合体
|
|
CN114716558B
(zh)
*
|
2022-04-12 |
2023-05-05 |
骏蓦(北京)生物科技有限公司 |
一种双特异性抗体及其治疗癌症的应用
|
|
AU2023256670A1
(en)
|
2022-04-21 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
CN119562820A
(zh)
|
2022-05-17 |
2025-03-04 |
优莫佳生物制药股份有限公司 |
制造病毒颗粒
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
EP4547230A1
(en)
|
2022-06-29 |
2025-05-07 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
JP2025531850A
(ja)
|
2022-09-08 |
2025-09-25 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
KR20250121163A
(ko)
|
2022-11-04 |
2025-08-11 |
우모자 바이오파마 인코포레이티드 |
융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
|
|
TW202434735A
(zh)
|
2022-11-04 |
2024-09-01 |
美商烏莫賈生物製藥股份有限公司 |
展示黏著分子融合的顆粒
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4633664A2
(en)
|
2022-12-13 |
2025-10-22 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024214593A1
(en)
|
2023-02-03 |
2025-08-07 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
TW202502363A
(zh)
|
2023-02-28 |
2025-01-16 |
美商奇諾治療有限公司 |
用於治療全身性自體免疫疾病之細胞療法
|
|
AU2024244733B2
(en)
|
2023-03-31 |
2025-12-11 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
CN121311765A
(zh)
|
2023-04-18 |
2026-01-09 |
朱诺治疗学股份有限公司 |
评估治疗性细胞组合物的效力的细胞毒性测定
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025235604A1
(en)
|
2024-05-08 |
2025-11-13 |
Umoja Biopharma, Inc. |
Fusion protein for use as immune cell engager
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|